PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-5.03
Both companies show losses. Martin Whitman would check if industry conditions create special situations.
4088.78
P/S 50-75% of TRAW's 8072.61. Bruce Berkowitz would examine if sales quality justifies the gap.
2.58
P/B less than half of TRAW's 13.79. David Dodd would verify if asset quality justifies this discount.
-31.79
Both companies show negative FCF. Martin Whitman would check for industry-wide capital intensity issues.
-32.20
Both companies show negative operating cash flow. Martin Whitman would check for industry-wide operational issues.
2.58
Fair value ratio less than half of TRAW's 13.79. David Dodd would verify if competitive position justifies this discount.
-4.97%
Both companies show losses. Martin Whitman would check for industry-wide issues.
-3.15%
Both companies show negative FCF. Martin Whitman would check for industry-wide capital intensity issues.